Altitude hypoxia and hypoxemia: pathogenesis and management

Area of Science:

• Environmental Physiology
• Altitude Medicine
• Pathophysiology

Background:

• High altitudes (>2500m) affect 80 million residents and 1 million visitors annually.
• Hypobaric hypoxia at altitude triggers physiological responses, but inadequate or excessive adaptation causes malacclimatization and altitude illnesses.
• Altitude illnesses range from acute (AMS, HACE, HAPE) to chronic (CMS, HAPH), stemming from acclimatization issues.

Purpose of the Study:

• To review current knowledge on clinical manifestations, epidemiology, and risk factors of high-altitude diseases.
• To systematically discuss recent pathophysiological mechanisms, focusing on genetic susceptibility and chronic altitude illnesses (CMS, HAPH).
• To provide a comprehensive overview of prevention and treatment strategies, highlighting natural and traditional Tibetan medicines.

Main Methods:

• Literature review of clinical manifestations, epidemiology, risk factors, and pathophysiology.
• Systematic discussion of recent pathophysiological mechanisms, including genetic factors.
• Overview of current prevention and treatment strategies, with emphasis on natural medicines.

Main Results:

• High-altitude illnesses are categorized as acute (AMS, HACE, HAPE) or chronic (CMS, HAPH) based on acclimatization adequacy.
• Pathophysiological mechanisms, especially for chronic conditions and genetic susceptibility, are under ongoing investigation.
• Natural medicines, particularly traditional Tibetan remedies, show promise in prevention and treatment.

Conclusions:

• Mechanisms underlying high-altitude illnesses are not fully understood, and management options remain limited.
• Further research is needed to elucidate pathogenic mechanisms and improve prevention and treatment strategies.
• Exploring genetic susceptibility and novel therapeutic approaches, including traditional medicines, is crucial for advancing altitude illness management.